Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 1 1

Status

Recruiting 3Not yet recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 7

Conditions

Multiple Myeloma 7Recurrence 1Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 43Lenalidomide 26daratumumab 23Bortezomib 23pomalidomide 22Cyclophosphamide 16Specimen Handling 14Biopsy 14carfilzomib 13Magnetic Resonance Spectroscopy 11talquetamab 10iberdomide 9fludarabine 9Calcium Dobesilate 9isatuximab 8Melphalan 8belantamab mafodotin 7selinexor 5fludarabine phosphate 5X-Rays 5elotuzumab 4Whole-Body Irradiation 4Nuclear Medicine Department, Hospital 4trametinib 3tocilizumab 3dexamethasone acetate 3dexamethasone 21-phosphate 3dabrafenib 3auricularum 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Multiple Myeloma × belantamab mafodotin × 30 days × Clear all
NCT04484623 2026-06-12

DREAMM 8

GlaxoSmithKline

Phase 3 Active not recruiting
302 enrolled 10 charts
Plasma cell

Multiple Myeloma

NCT07227311 2026-06-10

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

GlaxoSmithKline

Phase 2 Recruiting
200 enrolled
Plasma cell

Multiple Myeloma

NCT07614360 2026-05-29

DREAMM-16

GlaxoSmithKline

Phase 2 Not yet recruiting
120 enrolled
Plasma cell

Multiple Myeloma

NCT07609706 2026-05-27

A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

GlaxoSmithKline

Phase 1 Not yet recruiting
20 enrolled
Plasma cell

Multiple Myeloma

NCT05714839 2026-05-22

DREAMM-20

GlaxoSmithKline

Phase 1/2 Recruiting
152 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05853965 2026-05-18

BELI(E)VE

Universitätsklinikum Hamburg-Eppendorf

Phase 1/2 Recruiting
45 enrolled
Plasma cell

Multiple Myeloma

NCT07285239 2026-05-18

PrE1005

PrECOG, LLC.

Phase 3 Not yet recruiting
500 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡